A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1459-1467

  Hammond, Lisa A ^a,b,c   Eckardt, John R ^a,b,c   Ganapathi, Ram ^a,b,c   Burris, Howard A ^e   Rodriguez, Gladys A ^d   Eckhardt, S Gail ^a,b,c   Rothenberg, Mace L ^a,b,c   Weiss, Geoffery R ^a,b,c   Kuhn, John G ^a,b,c   Hodges, Stephanie ^a,b,c   Von Hoff, Daniel D ^a,b,c   Rowinsky, Eric K ^a,b,c  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DNA SEQUENCE; ENZYME INHIBITION; FEMALE; GENE TARGETING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RNA TRANSLATION; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TOPOTECAN;

EID: 17644445129     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 54: 665-697, 1985.
2. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351, 1989.
3. Caron, P., and Wang, J. C. DNA topoisomerases as targets of therapeutics: a structural overview. In: T. Andoh and O. M. Ikeda (eds.), Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy, pp. 1-18. Boca Raton, FL: CRC Press, 1993.
4. Andoh, T., and Ikeda, O. M. (eds.). Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. Boca Raton, FL: CRC Press, 1993.
5. Champoux, J. Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc. Natl. Acad. Sci. USA, 73: 3488-3491, 1976.
6. Champoux, J. Mechanisms of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to the 3′ terminus of the nicked DNA. J. Mol. Biol., 118: 441-446, 1978.
7. Champoux, J. DNA is linked to the rat liver DNA nicking-closing enzyme by a phosphodiester bond to tyrosine. J. Biol. Chem., 256: 4805-4809, 1981.
8. Lynn, R., Bjornsti, M. A., Caron, P., and Wang, J. C. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 86: 3559-3563, 1989.
9. Eng, W. K., Pandit, S. D., and Sternglanz, R. Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. J. Biol. Chem., 264: 13373-13376, 1989.
10. Goto, T., and Wang, J. C. Cloning of yeast TOP1, the encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and topoisomerase II. Proc. Natl. Acad. Sci. USA, 82: 7178-7182, 1985.
11. Brill, S. J., DiNardo, S., Voelkel-Meiman, K., and Sternglanz, R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature (Lond.), 326: 414-416, 1987.
12. Uemura, T., and Yanacida, M. Isolation of type I and II DNA mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J., 3: 1737-1744, 1984.
13. Thrash, C., Voelkel, K., DiNardo, S., and Sternglanz, R. Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase 1 activity. J. Biol. Chem., 259: 1375-1377, 1984.
14. Goto, T., and Wang, J. C. Cloning of yeast TOP1, the encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and topoisomerase II. Proc. Natl. Acad. Sci. USA, 82: 7178-7182, 1985.
15. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T., and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50: 6925-6930, 1990.
16. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51: 1129-1136, 1991.
17. Grabowski, D., and Ganapathi, R. Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multi-drug-resistant L1210 mouse leukemia cells. Ann. NY Acad. Sci., 803: 306-307, 1996.
18. Bertrand, R., O'Connor, P. M., Kerrigan, D., and Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer, 28A: 743-748, 1992.
19. D'Arpa, P., Beardmore, C., and Liu, L. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
20. Anzai, H., Frost, T., and Abbruzzese, J. L. Synergistic cytotoxicity with combined inhibition of topoisomerase (topo) I and II. Proc. Am. Assoc. Cancer Res., 33: 431, 1992.
21. Johnson, R., McCabe, F., and Yu, Y. Combination regimens with topotecan in animal tumor models. Ann. Oncol., 3: 85, 1992.
22. Whitacre, C. M., Zborowska, E., and Gordon, N. H. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res., 57: 1425-1428, 1997.
23. Tewey, K., Rowe, T., Yang, L., Halligan, B. D., and Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian topoisomerase II. Science (Washington DC), 226: 466-468, 1984.
24. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer, 50: 760-766, 1992.
25. Tan, K. B., Mattern, M. R., Eng, W. K., McCabe, F. L., and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst., 81: 1732-1735, 1989.
26. Rowinsky, E., Grochow, L., Hendricks, C., Ettinger, D., Forasteire, A., Hurowitz, L., McGuire, W., Sartorius, S., Lubejko, B., and Donehower, R. Phase I and pharmacologic study of topotecan (SK&F 104864): a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
27. Van Warmerdam, L. J. C., Venveij, J., Schellens, J. H. M., Rosing, H., Davies, B. E., De Boer-Dennert, M., Macs, R. A. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
28. Wall, J. G., Burris, H. A., Von Hoff, D. D., Rodriguez, G., Kneuper-Hall, R. Shaffer, D., O'Rourke, T., Brown, T., Weiss, G., Clark, G., McVea, S., Brown, J., Johnson, R., Freidman, C., Smith, B., Mann, W. S., and Kuhn, J. A Phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs, 3: 337-345, 1992.
29. Burris, H. A., Kuhn, J., Wall, J., Eckardt, J., Rodriguez, G., Johnson, R., Weiss, G., Shaffer, D., and Von Hoff, D. D. Early clinical trials of topotecan, a new topoisomerase I inhibitor. In: Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, p. 118. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1992.
30. Ardizzoni, A., Hansen, H., Dombernowsky, P., Postmus, P., Buitenhuis, M., Wanders, J., McDonald, M., and Giaccone, G. Phase II study of topotecan in pretreated small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 16: 283, 1996.
31. Creemers, G. J., Bolis, G., Gore, M., Scarfone, G., Lacave L. J., Gustalla, J. P., Despax, R., Favalli, G., Kreinberg, R., Van Belle, S., Hudson, I., Verweij, J., and ten Bokkel Huinink, W. W. Topotecan, an active drug in the second-line treatment of epithelian ovarian cancer: results of a large European Phase II study. J. Clin. Oncol., 14: 3056-3061, 1996.
32. Carmichael, J., Gordon, A., Malfetano, J., Gore, M., Spaczynski, M., Davidson, N., Savage, J., Clarke-Pearson, D., Hudson, I., Broom, C., and ten Bokkel Huinink, W. Topotecan, a new active drug, versus paclitaxel in advanced ovarian carcinoma: international topotecan study group trial. Proc. Am. Soc. Clin Oncol., 15: 283, 1996.
33. Eisenhauer, E. A., Wainman, G., Boos, G., MacDonald, V., and Bramwell, V. Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol., 13: 175, 1994.
34. Heideman, R., Kuttcsch, J., Stewart, C., Meyer, W., Bowman, L., Furman, W., Gajjar, A., Avery, L., and Pratt, C. A Phase I trial of a fixed systematic exposure of carboplatin with continuous infusion topotecan in pediatric solid tumors. Proc. Am. Soc. Clin. Oncol., 14: 447, 1995.
35. Kantarjian, H. M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., Koller, C., Rios, M., Plunkett, W., Keating, M. J., and Estey, E. H. Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed leukemia. Blood, 81: 1146-1151, 1993.
36. Perez-Soler, R., Fossella, F. U., Glisson, B. S., Lee, J. S., Murphy, W. K., Shin, D. M., Kemp, B. L., Lee, J. J., Kane, J., Robinson, R. A., Lippman, S. M., Kurie, J. M., Huber, M. H., Raber, M. N., and Hong, W. K. Phase II study in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol., 14: 503-513, 1996.
37. Robert, F., Wheeler, R. H., Molthrop, D. C., Greene, P., and Chen, S. Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent. Proc. Am. Soc. Clin. Oncol., 13: 281, 1994.
38. Rowinsky, E. K., Adjie, A. A., Donehower, R. C., Gore, S., Jones, R. J., Burke, P. J., Cheng, Y. C., Grochow, L. B., and Kaufman, S. H. A Phase I and pharmocodynamic study of topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 1994.
39. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 13, 1976.
40. Kuhn, J., Burris, H., and Irvin., R. Pharmacokinetics of topotecan following a 3 day continuous infusion. In: Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, p. 83. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1992.
41. Division of Cancer Treatment, National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: National Cancer Institute, 1988.
42. Kamath, N., Grabowski, D., Ford, J., Drake, F., Kerrigan, D., Pommier, Y., and Ganapathi, R. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells. Cancer Commun., 63: 37-44, 1991.
43. Kaufmann, S. H., McLaughlin, S. J., Kastan, M. B., Liu, L. F., Karp, J. E., and Burke, P. J. Topoisomerase II levels during granulocytic maturation in vivo and in vitro. Cancer Res., 57: 3534-3543, 1991.
44. Ganapathi, R., Kuo, T., Teeter, L., Grabowski, D., and Ford, J. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multi-drug resistant cells. Mol. Pharmacol., 39: 1-8, 1991.
45. Chang, J. Y., Demlefsen, L. A., Barley, L. R., Zhou, B. S., and Cheng, Y. C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443-2452, 1992.
46. Kaufmann, S. H., McLaughlin, S. J., Kastan, M. B., Liu, L. F., Karp, J. E., and Burke, P. J. Topoisomerase II levels during granulocytic maturation in vivo and in vitro. Cancer Res., 51: 3534-3543, 1991.
47. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1991.
48. Sinka, B. K. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs, 49: 11-19, 1995.
49. Herben, V. M. M. M. f., ten Bokkel Huinink, W. W., and Rodenhuis, S. Phase I. and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E). Eur. J. Cancer, 31A (Suppl. 5): S196, 1995.
50. Crump, M., Lipton, J., Hedley, D., Stewart, A. K., Sutton, D., Keating, A., Minden, M., Messner, H., and Eisenhauer, E. A Phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia (AML). Proc. Am. Soc. Clin. Oncol., 15: 357, 1996.
51. Cooper, B. W., Lazarus, H. M., and Creger, R. A Phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory relapsed acute leukemia (RAL). Proc. Am. Soc. Clin. Oncol., 15: 486, 1996.
52. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Blum, R. H., and Zelenuich-Jacquotte, A. Effect of prolonged topotecan infusion on topoisomerase I levels: a Phase I and pharmacodynamic study. Clin. Cancer Res., 3: 1245-1252, 1997.
53. Danks, M. K., Garrett, K. E., Marion, R. C., and Whipple, D. O. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res., 56: 1664-1673, 1996.